Increased expression of chemokine receptors CCR1 and CCR3 in nasal polyps: molecular basis for recruitment of the granulocyte infiltrate
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Eosinophils cytology MeSH
- Granulocytes cytology MeSH
- Humans MeSH
- Nasal Polyps genetics metabolism pathology MeSH
- Nasal Mucosa metabolism pathology MeSH
- Receptors, CCR1 genetics metabolism MeSH
- Receptors, CCR3 genetics metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- CCR1 protein, human MeSH Browser
- CCR3 protein, human MeSH Browser
- Receptors, CCR1 MeSH
- Receptors, CCR3 MeSH
Inflammatory processes play an important role in the development of nasal polyps (NP), but the etiology and, to a high degree also, the pathogenesis of NP are not fully understood. The role of several cytokines and chemokines such as eotaxins, IL-4, IL-5, IL-6, IL-8, and RANTES has been reported in NP. Herewith, we investigated the expression and pattern of distribution of chemokine receptors CCR1 and CCR3 in nasal polyps. Immunohistochemical detection was carried out in frozen sections of biopsies from 22 NP and 18 nasal mucosa specimens in both the epithelial and stromal compartments. Fluorescence microscopy and computerized image analysis revealed a statistically significant increased number of CCR1 (45.2 ± 2.8 vs. 15.1 ± 1.9, p < 0.001)-positive as well as CCR3 (16.4 ± 1.4 vs. 9.7 ± 1.1, p < 0.001)-positive cells in the stroma of NP compared to nasal mucosa. In comparison to healthy nasal mucosa, increased positivity of CCR3 was detected in the epithelial compartment of NP. Our data suggest that increased expression of CCR1 and CCR3 chemokine receptors may, in accord with various chemokines, contribute to the pathogenesis of nasal polyposis by facilitating increased migration and prolonged accumulation of inflammatory cells, e.g., eosinophils, in the inflammatory infiltrate of NP.
See more in PubMed
Eur Respir J. 1997 Jul;10(7):1489-95 PubMed
J Exp Med. 1996 May 1;183(5):2349-54 PubMed
Can J Gastroenterol. 2002 Apr;16(4):241-6 PubMed
Acta Otolaryngol. 2007 Apr;127(4):395-402 PubMed
Curr Opin Allergy Clin Immunol. 2003 Feb;3(1):1-6 PubMed
J Immunol. 2007 Dec 1;179(11):7585-92 PubMed
J Exp Med. 1993 May 1;177(5):1421-7 PubMed
J Clin Invest. 1996 Feb 1;97(3):604-12 PubMed
Int Arch Allergy Immunol. 1999 Aug;119(4):314-21 PubMed
Ann Otol Rhinol Laryngol. 1998 May;107(5 Pt 1):416-20 PubMed
J Allergy Clin Immunol. 1997 Jun;99(6 Pt 1):837-42 PubMed
Otolaryngol Head Neck Surg. 2004 May;130(5):526-35 PubMed
J Immunol. 2005 Jun 1;174(11):7341-51 PubMed
J Immunol. 1997 Apr 15;158(8):3902-8 PubMed
J Immunol. 2008 Dec 15;181(12):8670-6 PubMed
J Clin Invest. 1998 May 1;101(9):2017-24 PubMed
J Allergy Clin Immunol. 1998 Dec;102(6 Pt 1):953-60 PubMed
Dev Comp Immunol. 2004 May 3;28(5):443-60 PubMed
Allergy. 2003 Mar;58(3):176-91 PubMed
J Allergy Clin Immunol. 1993 Feb;91(2):616-22 PubMed
Clin Exp Allergy. 1994 Apr;24(4):307-17 PubMed
Pharmacol Rev. 2002 Jun;54(2):227-9 PubMed
J Allergy Clin Immunol. 2011 Jul;128(1):73-81.e4 PubMed
Cytokine. 2005 Jun 7;30(5):254-63 PubMed
Acta Otolaryngol. 1999;119(3):362-8 PubMed
Eur J Immunol. 1999 Apr;29(4):1324-33 PubMed
Laryngoscope. 2003 Aug;113(8):1374-7 PubMed
Acta Otolaryngol. 1998 Jun;118(3):404-8 PubMed
Science. 1997 Sep 26;277(5334):2005-7 PubMed
Am J Rhinol. 2005 Jan-Feb;19(1):15-20 PubMed
Folia Microbiol (Praha). 1998;43(5):545-50 PubMed
Clin Immunol. 2007 Sep;124(3):345-52 PubMed
Infect Immun. 2001 Jun;69(6):3772-81 PubMed
Cell. 1993 Feb 12;72(3):415-25 PubMed
Curr Allergy Asthma Rep. 2002 Nov;2(6):481-7 PubMed
Folia Microbiol (Praha). 2008;53(6):558-62 PubMed
Olfactory Evaluation in Clinical Medical Practice
